The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics.

ABSTRACT: Social anxiety disorder (SAD) is a highly prevalent psychiatric disorder that presents with an early age of onset, chronic disease course, and increased risk of psychiatric comorbidity. Current treatment options for SAD are associated with low response rates, suboptimal efficacy, and possible risk of adverse effects. Investigation of new neurobiological mechanisms may aid in the identification of more specific therapeutic targets for the treatment of this disorder. Emerging evidence suggests that the endogenous cannabinoid system, also referred to as the endocannabinoid system (ECS), could play a potential role in the pathophysiology of SAD. This review discusses the known pathophysiological mechanisms of SAD, the potential role of the ECS in this disorder, current drugs targeting the ECS,

SUBMITTER: Ahmed M 

PROVIDER: S-EPMC8827369 | biostudies-literature | 2022 Jan-Feb

REPOSITORIES: biostudies-literature